To investigate modulation of CD8+ T cell function, we utilized autologous culture assays that allowed activated CD8+ TILs to directly interact with FRCs for 24 hours prior to the addition of DLBCL B cells to measure antitumor activities (Figure 8A). This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.